Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
Open Access
- 1 January 1998
- journal article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 36 (6) , 433-436
- https://doi.org/10.1080/02681219880000691
Abstract
Voriconazole is a new triazole antifungal agent with potent activity against yeast and moulds. We investigated the in vitro activity of voriconazole, itraconazole, amphotericin B and 5-flucytosine against 51 clinical isolates of filamentous fungi. Overall, voriconazole was active (MIC50, 0·5 mgl-1 and MIC90, 8 mgl-1) against these mould isolates. Voriconazole was most active against P. boydii (MIC50, 0·12 mg l-1) and Aspergillus spp. (MIC90, 0·5 mgl-1) and least active against Fusarium spp. (MIC90, 8 mgl-1) and Rhizopus spp. (MIC50, 8 mgl-1). Voriconazole was more active than amphotericin B against Aspergillus spp. and P. boydii. By comparison with itraconazole, voriconazole was more active against all isolates except Rhizopus spp. Based on these results, voriconazole has promising activity against commonly encountered isolates of filamentous fungiand its clinical usefulness should be established by further studies.Keywords
This publication has 3 references indexed in Scilit:
- Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpointsJournal of Antimicrobial Chemotherapy, 1998
- In vitro evaluation of voriconazole against some clinically important fungiAntimicrobial Agents and Chemotherapy, 1997
- In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogensAntimicrobial Agents and Chemotherapy, 1997